Ardelyx (NASDAQ:ARDX): Q3 GAAP EPS of -$0.37.
Revenue of $3.01M (+1670.6% Y/Y)
Wednesday, November 6, 2019
AbbVie launches debt offering to fund Allergan merger
AbbVie (ABBV -0.1%) has initiated a private offering of senior unsecured notes aimed at funding its acquisition of Allergan (AGN -0.2%). Additional details unavailable at present.
Edwards Sapien 3 valve CE Mark’d for expanded use
Edwards Lifesciences (NYSE:EW) announces CE Mark certification for its SAPIEN 3 transcatheter heart valve for the treatment of patients diagnosed with aortic stenosis who are at low risk for open-heart surgery, the first transcatheter aortic valve implantation (TAVI) system to have this indication in Europe.
Horizon Pharma EPS beats by $0.14, beats on revenue
Horizon Pharma (NASDAQ:HZNP): Q3 Non-GAAP EPS of $0.64 beats by $0.14; GAAP EPS of $0.09 beats by $0.02.
Revenue of $335.5M (+3.1% Y/Y) beats by $4.9M.
Moderna misses on revenue
Moderna (NASDAQ:MRNA): Q3 Net loss of $123.19M.
Revenue of $17.05M (-59.2% Y/Y) misses by $0.59M.
Shares +0.06% PM.
Esperion Therapeutics EPS misses by $0.57, misses on revenue
Esperion Therapeutics (NASDAQ:ESPR): Q3 GAAP EPS of -$2.52 misses by $0.57.
Revenue of $0.98M misses by $0.01M.
Cash and equivalents of $211.98M.
Albireo Pharma EPS misses by $0.17, beats on revenue
Albireo Pharma (NASDAQ:ALBO): Q3 GAAP EPS of -$1.73 misses by $0.17.
Revenue of $1.39M (+479.2% Y/Y) beats by $0.43M.
Subscribe to:
Comments (Atom)